OpGen Announces Partial Adjournment of Annual Meeting
July 07 2021 - 4:30PM
OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision
medicine company harnessing the power of molecular diagnostics and
informatics to help combat infectious disease, today announced that
the Company resumed its partially adjourned 2021 annual
stockholders meeting (the “Annual Meeting”) on July 7, 2021, solely
with respect to Proposal 2 set forth in its Definitive Proxy
Statement, dated April 26, 2021, relating to the increase in the
Company’s authorized shares of common stock. The Company adjourned
the Annual Meeting with respect to such proposal to provide its
stockholders additional time to vote on Proposal 2. The Annual
Meeting will resume with respect to Proposal 2 at 10:00 a.m.
Eastern time on August 5, 2021 and will continue to be held at the
Company’s offices located at 9717 Key West Ave, Suite 100,
Rockville, MD 20850.* The record date for determining stockholders
eligible to vote at the Annual Meeting will remain the close of
business on April 15, 2021.
Oliver Schacht, CEO of OpGen commented: “We are
very encouraged by recent feedback and dialog with many
stockholders and the number of stockholders that have already voted
in favor of this important proposal. I cannot emphasize the
importance of this proposal enough for the ongoing success of the
Company. As such, our Board unanimously recommends this proposal be
approved. While OpGen had a strong cash position of $39.4 million
at the end of Q1-2021, these additional authorized shares will
provide the Company the necessary flexibility to seek future
financing to allow us to continue to expand, strategically manage
and potentially help repay our long-term debt, and raise additional
capital when needed. However, since we need at least 66.67% of all
of OpGen’s total shares outstanding to vote in favor of this
proposal for it to pass, management and our board of directors have
determined to concurrently explore alternative options for
financing the future development and growth of the Company.”
Stockholders as of close of business on
April 15, 2021, the record date for the Annual Meeting, who have
not yet voted are encouraged to vote over the Internet at
http://www.pstvote.com/opgen2021.
Stockholders needing assistance voting or have questions may
contact the Company’s proxy solicitation firm, Alliance Advisors,
LLC, at 800-574-6217 or
melissacarlson@allianceadvisors.com.
* As part of our precautions regarding the
coronavirus (or COVID-19) pandemic, we are planning for the
possibility that we may need to change the location of the Annual
Meeting, or the Annual Meeting may be held solely by means of
remote communication. If we take this step, we will announce the
decision to do so in advance, and details on how to participate
will be available on our website at
https://ir.opgen.com/.
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero®, Acuitas® AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb®,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements
This press release includes statements regarding
the partial adjournment of OpGen’s Annual Meeting. These
statements and other statements regarding OpGen’s Unyvero products,
their commercialization and launch, future plans and goals
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the fact that we may not effectively use proceeds from recent
financings, including our November 2020 private placement, February
2021 Registered Direct and March 2021 warrant exercise and
exchange, the realization of expected benefits of our business
combination transaction with Curetis GmbH, the success of our
commercialization efforts, the impact of COVID-19 on the Company’s
operations, financial results, and commercialization efforts as
well as on capital markets and general economic conditions, the
effect on our business of existing and new regulatory requirements,
and other economic and competitive factors. For a discussion of the
most significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen:Oliver SchachtPresident and
CEOInvestorRelations@opgen.com
OpGen Press Contact:Matthew
Bretzius FischTank Marketing and PR
matt@fischtankpr.com
OpGen Investor Contact:Joe Green Edison
Group jgreen@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024